Top Markets
Coin of the day
National Graphite Corp. National Graphite Corp.

National Graphite Corp.

NGRC
Rank in Stocks #35948
National Graphite Corp. (NGRC), operating through its subsidiary Biotech... National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.
Share Price
$0.021
Last synced: 2026-08-13
Market Cap
$3.24M
Change (1 day)
0.00%
Change (1 year)
-46.15%
Country
US
Trade National Graphite Corp. (NGRC)
P/B ratio for National Graphite Corp. (NGRC)
P/B ratio as of 2026 TTM: 0
According to National Graphite Corp. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for National Graphite Corp. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors